Inhibition of Yes-Associated Protein-1 (YAP1) Enhances the Response of Invasive Breast Cancer Cells to the Standard Therapy

References

• WintersS, MartinC, MurphyD, ShokarNK. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1–32.29096890
   PubMed Web of Science ®Google Scholar
• HaqueR, AhmedSA, InzhakovaG, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1848–1855. doi:10.1158/1055-9965.EPI-12-047422989461
   PubMed Web of Science ®Google Scholar
• PorazinskiS, WangH, AsaokaY, et al. YAP is essential for tissue tension to ensure vertebrate 3D body shape. Nature. 2015;521(7551):217–221.25778702
   PubMed Web of Science ®Google Scholar
• HagenbeekTJ, WebsterJD, KljavinNM, et al. The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors. Sci Signal. 2018;11(547):547. doi:10.1126/scisignal.aaj1757
   Web of Science ®Google Scholar
• ZanconatoF, CordenonsiM, PiccoloS. YAP/TAZ at the roots of cancer. Cancer Cell. 2016;29(6):783–803. doi:10.1016/j.ccell.2016.05.00527300434
   PubMed Web of Science ®Google Scholar
• SteinhardtAA, GayyedMF, KleinAP, et al. Expression of Yes-associated protein in common solid tumors. Hum Pathol. 2008;39(11):1582–1589. doi:10.1016/j.humpath.2008.04.01218703216
   PubMed Web of Science ®Google Scholar
• WangX, SuL, OuQ. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer. 2012;48(8):1227–1234. doi:10.1016/j.ejca.2011.10.00122056638
   PubMed Web of Science ®Google Scholar
• YuanM, TomlinsonV, LaraR, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ. 2008;15(11):1752–1759. doi:10.1038/cdd.2008.10818617895
   PubMed Web of Science ®Google Scholar
• ZhuP, WangY, WuJ, et al. LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells. Nat Commun. 2016;7(1):13608. doi:10.1038/ncomms1360827905400
   PubMed Web of Science ®Google Scholar
• WangD, LuP, ZhangH, et al. Oct-4 and nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget. 2014;5(21):10803–10815. doi:10.18632/oncotarget.250625301732
   PubMed Web of Science ®Google Scholar
• HenneyJE. From the food and drug administration. JAMA. 2000;283(21):2779. doi:10.1001/jama.283.21.2779-JFD00004-2-110896520
   PubMedGoogle Scholar
• Liu-ChittendenY, HuangB, ShimJS, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26(12):1300–1305. doi:10.1101/gad.192856.11222677547
   PubMed Web of Science ®Google Scholar
• BrodowskaK, Al-MoujahedA, MarmalidouA, et al. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res. 2014;124:67–73. doi:10.1016/j.exer.2014.04.01124837142
   PubMed Web of Science ®Google Scholar
• FengJ, GouJ, JiaJ, YiT, CuiT, LiZ. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer. Onco Targets Ther. 2016;9:5371–5381. doi:10.2147/OTT.S10997927621651
   PubMed Web of Science ®Google Scholar
• GuimeiM, EladlMA, RanadeAV, ManzoorS. Autophagy related markers (Beclin-1 and ATG4B) are strongly expressed in Wilms’ tumor and correlate with favorable histology. Histol Histopathol. 2019;34(1):47–56.29989143
   PubMed Web of Science ®Google Scholar
• VlugEJ, van de VenRAH, VermeulenJF, BultP, van DiestPJ, DerksenPWB. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol. 2013;36(5):375–384. doi:10.1007/s13402-013-0143-7
   PubMed Web of Science ®Google Scholar
• KimHM, JungWH, KooJS. Expression of Yes-associated protein (YAP) in metastatic breast cancer. Int J Clin Exp Pathol. 2015;8(9):11248–11257.26617849
   PubMed Web of Science ®Google Scholar
• TufailR, JordaM, ZhaoW, ReisI, NawazZ. Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Res Treat. 2012;131(3):743–750. doi:10.1007/s10549-011-1435-021399893
   PubMed Web of Science ®Google Scholar
• CaoL, SunPL, YaoM, JiaM, GaoH. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues. Hum Pathol. 2017;68:166–174. doi:10.1016/j.humpath.2017.08.03228899737
   PubMed Web of Science ®Google Scholar
• DhananjayanSC, RamamoorthyS, KhanOY, et al. WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. Mol Endocrinol. 2006;20(10):2343–2354. doi:10.1210/me.2005-053316772533
   PubMedGoogle Scholar
• ZhuC, LiL, ZhangZ, et al. A non-canonical role of YAP/TEAD is required for activation of estrogen-regulated enhancers in breast cancer. Mol Cell. 2019;75(4):791–806.e798. doi:10.1016/j.molcel.2019.06.01031303470
   PubMed Web of Science ®Google Scholar
• OhgushiM, MinaguchiM, Rho-Signaling-DirectedSY. YAP/TAZ activity underlies the long-term survival and expansion of human embryonic stem cells. Cell Stem Cell. 2015;17(4):448–461. doi:10.1016/j.stem.2015.07.00926321201
   PubMed Web of Science ®Google Scholar
• ParkJH, ShinJE, ParkHW. The role of Hippo pathway in cancer stem cell biology. Mol Cells. 2018;41(2):83–92.29429151
   PubMed Web of Science ®Google Scholar
• ShibataM, HamK, HoqueMO. A time for YAP1: tumorigenesis, immunosuppression and targeted therapy. Int J Cancer. 2018;143(9):2133–2144. doi:10.1002/ijc.3156129696628
   PubMed Web of Science ®Google Scholar
• ShibueT, WeinbergRA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–629.28397828
   PubMed Web of Science ®Google Scholar
• OokiA, Del Carmen Rodriguez PenaM, MarchionniL, et al. YAP1 and COX2 coordinately regulate urothelial cancer stem-like cells. Cancer Res. 2018;78(1):168–181. doi:10.1158/0008-5472.CAN-17-083629180467
   PubMed Web of Science ®Google Scholar
• NotoA, De VitisC, PisanuME, et al. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. Oncogene. 2017;36(32):4573–4584. doi:10.1038/onc.2017.7528368399
   PubMed Web of Science ®Google Scholar
• Bora-SinghalN, NguyenJ, SchaalC, et al. YAP1 regulates OCT4 activity and SOX2 expression to facilitate self-renewal and vascular mimicry of stem-like cells. Stem Cells. 2015;33(6):1705–1718. doi:10.1002/stem.199325754111
   PubMed Web of Science ®Google Scholar
• ZhengL, XiangC, LiX, et al. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling. J Hematol Oncol. 2018;11(1):72. doi:10.1186/s13045-018-0613-529848346
   PubMed Web of Science ®Google Scholar
• AlmozyanS, ColakD, MansourF, et al. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation. Int J Cancer. 2017;141(7):1402–1412. doi:10.1002/ijc.3083428614911
   PubMed Web of Science ®Google Scholar
• DongL, LinF, WuW, LiuY, HuangW. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway. Int J Med Sci. 2018;15(6):645–652. doi:10.7150/ijms.2346029725256
   PubMed Web of Science ®Google Scholar
• WangC, ZhuX, FengW, et al. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J Cancer Res. 2015;6(1):27–37.27073720
   PubMed Web of Science ®Google Scholar